• Product NameGZD824 Dimesylate
• Brief DescriptionInhibitors
• Purification99.50%
• Biological ActivityGZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
• Target NameBcr-Abl inhibitor
• CAS No. 1421783-64-3
• Calculated MW 724.77
• Formulation C29H27F3N6O2CH4O3S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CS(O)(=O)=O.CS(O)(=O)=O.CN1CCN(CC2=C(C=C(NC(=O)C3=CC(C#CC4=CC5=C(NN=C5)N=C4)=C(C)C=C3)C=C2)C(F)(F)F)CC1
  Pathways:Angiogenesis; Cytoskeletal Signaling
  Receptor:Abl; Abl (E255K); Abl (H396P); Abl (M351T); Abl (Q252H)
  Boling pt:
  Melting pt:
  Solubility:Water: 100 mg/mL (137.97 mM); DMSO: 100 mg/mL (137.97 mM)
  Appearance:Faint Yellow Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Ren X, et al. J Med Chem. 2013, 56(3), 879-894.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting